Cargando…
Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
Cardiotoxicity is a relatively frequent and potentially serious side effect of anticancer treatments, particularly anthracyclines and trastuzumab, widely used in the treatment of breast cancer. The increase in cancer survivors has generated a growing interest in the prevention of cardiotoxicity. Alt...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120962/ https://www.ncbi.nlm.nih.gov/pubmed/37091667 http://dx.doi.org/10.1093/eurheartjsupp/suad062 |
_version_ | 1785029280188596224 |
---|---|
author | Bisceglia, Irma Mistrulli, Raffaella Cartoni, Domenico Matera, Sabrina Petrolati, Sandro Canale, Maria Laura |
author_facet | Bisceglia, Irma Mistrulli, Raffaella Cartoni, Domenico Matera, Sabrina Petrolati, Sandro Canale, Maria Laura |
author_sort | Bisceglia, Irma |
collection | PubMed |
description | Cardiotoxicity is a relatively frequent and potentially serious side effect of anticancer treatments, particularly anthracyclines and trastuzumab, widely used in the treatment of breast cancer. The increase in cancer survivors has generated a growing interest in the prevention of cardiotoxicity. Although early studies suggested an overall benefit on cardiac function with the use of ACE inhibitors (ACEIs) and beta blockers (BBs), more recent randomized trials have demonstrated little or no effect of pharmacological interventions. Even the various meta-analyses conducted in this area have provided weak results in favour of cardioprotective therapies for which the benefit would not always justify the risk of developing side effects. Given the incompleteness of the evidence, there is no clear consensus on which patients should initiate cardioprotective therapy. As recommended in the new guidelines of the European Society of Cardiology, risk stratification before treatment is crucial to identify high-risk patients who would benefit most from the use of cardioprotective therapy. Randomized trials are currently underway to evaluate other therapeutic strategies such as sacubitril/valsartan, and the possibility of using gliflozins in the future cannot be excluded. However, rigorous control and treatment of risk factors remain the primary focus in the management of these patients. |
format | Online Article Text |
id | pubmed-10120962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101209622023-04-22 Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? Bisceglia, Irma Mistrulli, Raffaella Cartoni, Domenico Matera, Sabrina Petrolati, Sandro Canale, Maria Laura Eur Heart J Suppl CCC 2023 - State of the Art Cardiology Supplement Paper Cardiotoxicity is a relatively frequent and potentially serious side effect of anticancer treatments, particularly anthracyclines and trastuzumab, widely used in the treatment of breast cancer. The increase in cancer survivors has generated a growing interest in the prevention of cardiotoxicity. Although early studies suggested an overall benefit on cardiac function with the use of ACE inhibitors (ACEIs) and beta blockers (BBs), more recent randomized trials have demonstrated little or no effect of pharmacological interventions. Even the various meta-analyses conducted in this area have provided weak results in favour of cardioprotective therapies for which the benefit would not always justify the risk of developing side effects. Given the incompleteness of the evidence, there is no clear consensus on which patients should initiate cardioprotective therapy. As recommended in the new guidelines of the European Society of Cardiology, risk stratification before treatment is crucial to identify high-risk patients who would benefit most from the use of cardioprotective therapy. Randomized trials are currently underway to evaluate other therapeutic strategies such as sacubitril/valsartan, and the possibility of using gliflozins in the future cannot be excluded. However, rigorous control and treatment of risk factors remain the primary focus in the management of these patients. Oxford University Press 2023-04-21 /pmc/articles/PMC10120962/ /pubmed/37091667 http://dx.doi.org/10.1093/eurheartjsupp/suad062 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | CCC 2023 - State of the Art Cardiology Supplement Paper Bisceglia, Irma Mistrulli, Raffaella Cartoni, Domenico Matera, Sabrina Petrolati, Sandro Canale, Maria Laura Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title | Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title_full | Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title_fullStr | Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title_full_unstemmed | Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title_short | Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
title_sort | cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect? |
topic | CCC 2023 - State of the Art Cardiology Supplement Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120962/ https://www.ncbi.nlm.nih.gov/pubmed/37091667 http://dx.doi.org/10.1093/eurheartjsupp/suad062 |
work_keys_str_mv | AT biscegliairma cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect AT mistrulliraffaella cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect AT cartonidomenico cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect AT materasabrina cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect AT petrolatisandro cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect AT canalemarialaura cardiactoxicityofchemotherapyforbreastcancerdoangiotensinconvertingenzymeinhibitorsandbetablockersprotect |